Corifollitropin alfa versus follitropin beta: an economic analysis alongside a randomized controlled trial in women undergoing IVF/ICSI
Le Dang Khoaa,⁎, Vuong Thi Ngoc Lanb, Nguyen Minh Tai Locc, Dang Quang Vinhc, Quang Nhat Tranb,d, Ho Manh Tuonga
This cost-effectiveness analysis was conducted from the patient’s perspective alongside a randomized controlled trial comparing corifollitropin alfa with follitropin beta for a single stimulation cycle. Only unit costs paid by patients are included in this analysis. The incremental cost-effectiveness ratio was calculated. One-way sensitivity analysis and probabilistic sensitivity analysis (PSA) were also performed. Baseline characteristics (except for the number of follicles and frozen embryos), treatment outcomes and complications were similar in the two groups. The live birth rate was comparable between the two groups, but the mean total cost per patient was higher for the corifollitropin alfa strategy (€4293) compared with the follitropin beta strategy (€4086). Costs per live birth were €13,726 and €12,511, respectively. The difference in effect between corifollitropin alfa and collitropin beta was three fewer live births, and the difference in costs was €24,048. The probability of live birth after the first and second embryo transfers and the proportion of patients who had no more frozen embryos available after non-achievement of live birth in the first or second transfer influenced the comparative cost-effectiveness of the two strategies. PSA showed that a corifollitropin alfa strategy would be rejected in up to 27.4% of scenarios. Follitropin beta 300 IU/day was more cost-effective than corifollitropin alfa 150 μg in women aged 35–42 years weighing ≥ 50 kg undergoing in-vitro fertilzation/intracytoplasmic sperm injection.
cost-effectiveness, corifollitropin alfa, follitropin beta, IVFI, CSI
Review Cervical pessary vs vaginal progesterone for the prevention of preterm birth in women with twin pregnancies and a short cervix: an economic analysis alongside a randomized controlled trial
[ Le KD1, Nguyen LK2, Nguyen LTM2, Mol BWJ3, Dang VQ1,2 ]
Review Predictive Model for Live Birth at 12 Months After Starting In-Vitro Fertilization Treatment
[ Vu NA Ho 1, Toan D Pham 1, Tuong M Ho 1, Lan N Vuong 1 ,2 ]
IVF carries a considerable physical, emotional and financial burden. Therefore, it would be useful to be able to predi...
Review Standardizing definitions and reporting guidelines for the infertility core outcome set: an international consensus development study
[ J. M. N. Duffy,a,b S. Bhattacharya,c S. Bhattacharya,c M. Bofill,d B. Collura,e C. Curtis,f,g J. L. H. Evers,h L. C. Giudice,i,j R. G. Farquharson,k S. Franik,l M. Hickey,m M. L. Hull,n V. Jordan,d Y. Khalaf,o R. S. Legro,p S. Lensen,m D. Mavrelos,q B. W. Mol,r C. Niederberger,s E. H. Y. Ng,t,u L. Puscasiu,v S. Repping,w,x I. Sarris,a M. Showell,y A. Strandell,z A. Vail,aa M. van Wely,w M. Vercoe,y N. L. Vuong,bb A. Y. Wang,cc R. Wang,r J. Wilkinson,aa M. A. Youssef,dd C. M. arquhard,y and the Core Outcome Measure for Infertility Trials (COMMIT) initiativez ]
Study Question: Can consensus definitions for the core outcome set for infertility be identified in o...
Review Pessary Compared With Vaginal Progesterone for the Prevention of Preterm Birth in Women With Twin Pregnancies and Cervical Length Less Than 38 mm - A Randomized Controlled Trial
[ Dang, Vinh Q.1; Nguyen, Linh K.1; Pham, Toan D.1; He, Yen T. N.1; Vu, Khang N.1; Phan, Minh T. N.1; Le, Thanh Q.2; Le, Cam H.1; Vuong, Lan N.1,3; Mol, Ben W.4 ]
OBJECTIVE: To compare the effectiveness of cervical...
Review Gonadotropin-Releasing Hormone Agonist Versus Human Chorionic Gonadotropin for Ovulation Induction in Polycystic Ovary Syndrome Patients Undergoing Intrauterine Insemination: A Randomised Controlled Trial
[ Anh N. Ha1,*, Toan D. Pham1,2, Vinh Q. Dang1,2, Lan N. Vuong1,3, Tuong M. Ho1,2 ]
Gonadotropins have been recommended to improve ovula...